aTYR PHARMA INC Cash and Cash Equivalents
aTYR PHARMA INC (ATYR) had Cash and Cash Equivalents of $16.16 million as of 2026-06-30, per its 10-Q filed 2026-08-07.
Financial Statements › Balance Sheet › Assets › Assets, Current › Cash, Cash Equivalents, and Short-Term Investments
us-gaap:CashAndCashEquivalentsAtCarryingValue · last filed 2026-08-07
- 2026-06-30: Cash and Cash Equivalents, at Carrying Value $16.16M.
- 2026-03-31: Cash and Cash Equivalents, at Carrying Value $10.01M.
- 2025-12-31: Cash and Cash Equivalents, at Carrying Value $10.74M.
- 2025-09-30: Cash and Cash Equivalents, at Carrying Value $6.15M.
| Period end | Cash and Cash Equivalents, at Carrying Value |
|---|---|
| 2026-06-30 | $16.16M 10-Q · filed 2026-08-07 |
| 2026-03-31 | $10.01M 10-Q · filed 2026-05-15 |
| 2025-12-31 | $10.74M 10-Q · filed 2026-08-07 |
| 2025-09-30 | $6.15M 10-Q · filed 2025-11-06 |
| 2025-06-30 | $17.22M 10-Q · filed 2026-08-07 |
| 2025-03-31 | $10.36M 10-Q · filed 2026-05-15 |
| 2024-12-31 | $11.05M 10-K · filed 2026-03-05 |
| 2024-09-30 | $11.46M 10-Q · filed 2025-11-06 |
| 2024-06-30 | $6.80M 10-Q · filed 2025-08-07 |
| 2024-03-31 | $6.81M 10-Q · filed 2025-05-07 |
| 2023-12-31 | $22.54M 10-K · filed 2026-03-05 |
| 2023-09-30 | $9.79M 10-Q · filed 2024-11-07 |
| 2023-06-30 | $12.31M 10-Q · filed 2024-08-13 |
| 2023-03-31 | $20.69M 10-Q · filed 2024-05-02 |
| 2022-12-31 | $9.98M 10-K · filed 2025-03-13 |
| 2022-09-30 | $18.36M 10-Q · filed 2023-11-09 |
| 2022-06-30 | $8.48M 10-Q · filed 2023-08-09 |
| 2022-03-31 | $8.32M 10-Q · filed 2023-05-09 |
| 2021-12-31 | $2.34M 10-K · filed 2024-03-14 |
| 2021-09-30 | $59.74M 10-Q · filed 2022-11-14 |
| 2021-06-30 | $2.19M 10-Q · filed 2022-08-15 |
| 2021-03-31 | $12.59M 10-Q · filed 2021-05-14 |
| 2020-12-31 | $16.95M 10-K · filed 2023-03-14 |
| 2020-09-30 | $18.15M 10-Q · filed 2020-11-13 |
| 2020-06-30 | $21.63M 10-Q · filed 2020-08-13 |
| 2020-03-31 | $39.45M 10-Q · filed 2020-05-12 |
| 2019-12-31 | $9.21M 10-K · filed 2021-03-24 |
| 2019-09-30 | $17.34M 10-Q · filed 2019-11-14 |
| 2019-06-30 | $14.51M 10-Q · filed 2019-08-14 |
| 2019-03-31 | $12.96M 10-Q · filed 2019-05-14 |
| 2018-12-31 | $22.96M 10-K · filed 2020-03-26 |
| 2018-09-30 | $31.55M 10-Q · filed 2018-11-14 |
| 2018-06-30 | $19.27M 10-Q · filed 2019-08-14 |
| 2018-03-31 | $21.94M 10-Q · filed 2019-05-14 |
| 2017-12-31 | $21.09M 10-Q · filed 2019-08-14 |
| 2017-09-30 | $29.77M 10-Q · filed 2018-11-14 |
| 2017-06-30 | $35.91M 10-Q · filed 2018-08-14 |
| 2017-03-31 | $28.90M 10-Q · filed 2018-05-15 |
| 2016-12-31 | $38.39M 10-K · filed 2019-03-26 |
| 2016-09-30 | $34.33M 10-Q · filed 2017-11-14 |
| 2016-06-30 | $43.19M 10-Q · filed 2017-08-14 |
| 2016-03-31 | $54.10M 10-Q · filed 2017-05-11 |
| 2015-12-31 | $53.02M 10-K · filed 2019-03-26 |
| 2015-09-30 | $60.05M 10-Q · filed 2016-11-14 |
| 2015-06-30 | $63.07M 10-Q · filed 2016-08-10 |
| 2015-03-31 | $54.51M 10-Q · filed 2016-05-11 |
| 2014-12-31 | $13.90M 10-K · filed 2018-03-20 |
| 2014-09-30 | $18.73M 10-Q · filed 2015-11-10 |
| 2014-06-30 | $24.64M 10-Q · filed 2015-08-12 |
| 2014-03-31 | $24.52M 10-Q · filed 2015-06-18 |
| 2013-12-31 | $36.46M 10-K · filed 2017-03-16 |
| 2012-12-31 | $3.67M 10-K · filed 2016-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Quince Therapeutics, Inc. (QNCX) | United States | $0.031B | |
| CEL SCI CORP (CVM) | United States | $0.030B | -0.81 |
| Scilex Holding Co (SCLX) | United States | $0.042B | -0.14 |
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| Estrella Immunopharma, Inc. (ESLA) | United States | $0.020B | |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| BioCardia, Inc. (BCDA) | United States | $0.016B |